Resources Repository
-
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Health Outcomes | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Global Governance | Economics/Finance | Science/Technology | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Health Outcomes | State-Transition | Dynamic Transmission | Microsimulation | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Economics/Finance | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2017Using Data-Driven Agent-Based Models to Forecast Emerging Infectious Diseases
This paper describes an agent-based model framework developed to forecast the 2014-15 Ebola epidemic, which …
This paper describes an agent-based model framework developed to forecast the 2014-15 Ebola epidemic, which was subsequently used in the Ebola forecasting challenge. Producing timely and reliable forecasts for an epidemic of an emerging infectious disease is a challenge. Epidemiologists and policy makers have to deal with poor data quality, limited understanding of the disease dynamics, a rapidly changing social environment and the uncertainty around the effects of various interventions in place. In this setting,…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Microsimulation | Calibration/Validation | Dynamic Simulation -
ArticlePublication 2007Economic Evaluation of Hepatitis B Vaccination in Low-Income Countries: Cost-Effectiveness Affordability Curves
In the face of uncertainties about both the health and economic consequences of a vaccine …
In the face of uncertainties about both the health and economic consequences of a vaccine program, as well as the availability and magnitude of resources needed to fund the program, cost-effectiveness affordability curves can provide information to decision-makers about the probability that a program will be both cost-effective and affordable: these are distinct but equally relevant considerations in resource-poor settings. This paper describes the application of this method to assess a hepatitis B vaccination program in the…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Costing Methods | Mathematical Models | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Health Systems | Economics/Finance -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Health Outcomes | Mathematical Models | Calibration/Validation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Global | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2013Validation and Calibration of a Simulation Model of Pediatric HIV Infection
The authors developed a microsimulation model of pediatric HIV disease progression using the Cost-Effectiveness of …
The authors developed a microsimulation model of pediatric HIV disease progression using the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model framework. This CEPAC-Pediatric model was then validated by varying CD4 data and comparing the corresponding model-generated survival curves to empirical survival curves obtained from the International Epidemiologic Database to Evaluate AIDS (IeDEA). The model was calibrated to other African countries by systematically varying immunologic and HIV mortality-related input parameters. In the calibration analyses, the model-generated…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Microsimulation | Calibration/Validation | Child/Nutrition -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Microsimulation | Calibration/Validation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Clinical Care | Economics/Finance | Science/Technology -
ArticlePublication 2010Health and Economic Impact of Rotavirus Vaccination in GAVI-Eligible Countries
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately …
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Motivated by the global recommendation by the WHO that all countries include infant rotavirus vaccination in their national immunization programs, the objective of this analysis was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. The authors synthesized population-level data from various sources (primarily from…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Health Outcomes | Mathematical Models | State-Transition | Cost-Effectiveness Analysis | Child/Nutrition | Economics/Finance | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2024Hepatitis C Elimination in Rwanda: Progress, Feasibility, Economic Evaluation
This study evaluates the impact of Rwanda's national program launched in 2018 to eliminate hepatitis …
This study evaluates the impact of Rwanda's national program launched in 2018 to eliminate hepatitis C virus (HCV) and identifies strategies to achieve World Health Organization (WHO) elimination goals by 2030. Employing a microsimulation model spanning 2015 to 2050, the analysis assesses HCV epidemic trends, prevalence, mortality, and total care costs under various scenarios. Results show that between 2018 and 2022, over 7 million people were screened and 60,000 treated, projecting Rwanda's potential achievement of…
Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Microsimulation | Chronic Disease/Risk